Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00Defense World · Oct 6, 2026
812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DEDefense World · Sep 28, 2026
5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryZacks Investment Research · Sep 14, 2026
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewsWire · Sep 1, 2026
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)Zacks Investment Research · Aug 31, 2026
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research · Aug 25, 2026Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.20 | -$0.11 | Beat |
| May 12, 2026 | -$0.18 | -$0.22 | Miss |
| Mar 19, 2026 | -$0.14 | -$0.27 | Miss |
| Nov 13, 2025 | -$0.04 | -$0.30 | Miss |
| Aug 7, 2025 | -$0.25 | -$0.30 | Miss |
| May 12, 2025 | -$0.31 | -$0.58 | Miss |